Free Trial

Avidity Biosciences (RNA) Stock Price, News & Analysis

Avidity Biosciences logo
$35.92 -0.79 (-2.15%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$36.44 +0.52 (+1.45%)
As of 08/1/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Avidity Biosciences Stock (NASDAQ:RNA)

Key Stats

Today's Range
$35.49
$36.70
50-Day Range
$28.40
$36.88
52-Week Range
$21.51
$56.00
Volume
2.25 million shs
Average Volume
2.80 million shs
Market Capitalization
$4.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.35
Consensus Rating
Buy

Company Overview

Avidity Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

RNA MarketRank™: 

Avidity Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 433rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 16 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Avidity Biosciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Avidity Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avidity Biosciences is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avidity Biosciences is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avidity Biosciences has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Avidity Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.49% of the outstanding shares of Avidity Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Avidity Biosciences has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avidity Biosciences has recently decreased by 2.75%, indicating that investor sentiment is improving.
  • Dividend Yield

    Avidity Biosciences does not currently pay a dividend.

  • Dividend Growth

    Avidity Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.49% of the outstanding shares of Avidity Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Avidity Biosciences has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avidity Biosciences has recently decreased by 2.75%, indicating that investor sentiment is improving.
  • News Sentiment

    Avidity Biosciences has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Avidity Biosciences this week, compared to 8 articles on an average week.
  • Search Interest

    10 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $875,969.00 in company stock.

  • Percentage Held by Insiders

    Only 3.83% of the stock of Avidity Biosciences is held by insiders.

  • Read more about Avidity Biosciences' insider trading history.
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Stock News Headlines

A new rule goes live in July — and the banks are quietly crushing it
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

RNA Stock Analysis - Frequently Asked Questions

Avidity Biosciences' stock was trading at $29.08 at the beginning of 2025. Since then, RNA shares have increased by 23.5% and is now trading at $35.92.

Avidity Biosciences, Inc. (NASDAQ:RNA) released its quarterly earnings results on Thursday, May, 8th. The biotechnology company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.88) by $0.02. The biotechnology company earned $1.60 million during the quarter, compared to analysts' expectations of $2.63 million. Avidity Biosciences had a negative net margin of 4,136.00% and a negative trailing twelve-month return on equity of 26.96%.

Avidity Biosciences (RNA) raised $150 million in an IPO on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

Top institutional shareholders of Avidity Biosciences include TD Asset Management Inc (0.34%), Mutual of America Capital Management LLC (0.15%), Envestnet Asset Management Inc. (0.05%) and State of New Jersey Common Pension Fund D (0.05%). Insiders that own company stock include Sarah Boyce, Teresa Mccarthy, Michael F Maclean, W Michael Flanagan, Steven George Hughes, Kathleen P Gallagher, Arthur A Levin and Tamar Thompson.
View institutional ownership trends
.

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/08/2025
Today
8/01/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNA
CIK
1599901
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

High Price Target
$96.00
Low Price Target
$50.00
Potential Upside/Downside
+84.7%
Consensus Rating
Buy
Rating Score (0-4)
3.06
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$322.30 million
Net Margins
-4,136.00%
Pretax Margin
-4,135.99%
Return on Equity
-26.96%
Return on Assets
-24.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.91
Quick Ratio
16.91

Sales & Book Value

Annual Sales
$10.90 million
Price / Sales
397.16
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.94 per share
Price / Book
3.01

Miscellaneous

Outstanding Shares
120,520,000
Free Float
115,904,000
Market Cap
$4.33 billion
Optionable
Optionable
Beta
0.91

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:RNA) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners